BenevolentAI Investor Presentation Deck

BEN-2293 is progressing in an adaptive Phase I/II clinical study, with full data expected end of 2022 Part A 1 2 First in Human Dose Escalation 3 Part A Completed Dec 2021 8 Mild-Moderate AD patients (18-65 years) per cohort, randomised 3:1 BEN-2293:Placebo Safety, Tolerability, PK Adaptive ascending dose cohort design Includes efficacy endpoints MALDI imaging (evaluate human skin PK) SRC: Safety Review Committee Part A ✓ Complete SRC approval for progression to Part B Part B: Protocol under final Ethics review Part B Efficacy Cohort(s) Full data expected end of 2022 45 Mild-Moderate AD patients (18-65 years) per arm, 28 day dosing. Efficacy Outcome measures include itch (NRS) and inflammation (VIGA, EASI) Additional safety, tolerability and PK Biomarker panel (reflects PanTrk mechanism and AD effect) Our intention is to out-licence development and commercialisation of BEN-2293 following completion of this trial, with key Big Pharma and Dermatology specialists as potential partners Benevolent 12

View entire presentation